Tag Archives: Mayank Mamtani

Analysts Offer Insights on Healthcare Companies: Agenus (NASDAQ: AGEN), Coherus Biosciences (NASDAQ: CHRS) and Fate Therapeutics (NASDAQ: FATE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agenus (AGEN – Research Report), Coherus Biosciences (CHRS – Research Report) and Fate Therapeutics (FATE – Research Report) with bullish sentiments. Agenus

B.Riley FBR Keeps a Buy Rating on Akari Therapeutics (AKTX)

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Akari Therapeutics (AKTX – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $1.56. According to TipRanks.com, Mamtani is

B.Riley FBR Reiterates Their Buy Rating on X4 Pharmaceuticals (XFOR)

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of $15.00. The company’s shares closed last Thursday at $8.00. According to TipRanks.com, Mamtani is a 5-star analyst

Analyst Explains Why They Downgraded Their Rating on Acasti Pharma (ACST)

In a report released today, Mayank Mamtani from B.Riley FBR downgraded Acasti Pharma (ACST – Research Report) to Hold, with a price target of $0.50. The company’s shares closed last Monday at $0.24. According to TipRanks.com, Mamtani is a 5-star

Fortress Biotech (FBIO) Receives a Buy from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Fortress Biotech (FBIO – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $3.91. According to TipRanks.com, Mamtani is

Viking Therapeutics (VKTX) Receives a Buy from B.Riley FBR

In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $12.00. The company’s shares closed last Friday at $6.90. According to TipRanks.com, Mamtani is